Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Longitudinal decline in speech production in Parkinson's disease spectrum disorders.

Ash S, Jester C, York C, Kofman OL, Langey R, Halpin A, Firn K, Dominguez Perez S, Chahine L, Spindler M, Dahodwala N, Irwin DJ, McMillan C, Weintraub D, Grossman M.

Brain Lang. 2017 Aug;171:42-51. doi: 10.1016/j.bandl.2017.05.001. Epub 2017 May 17.

PMID:
28527315
2.

Dementia-Free Survival and Risk Factors for Dementia in a Hospital-Based Korean Parkinson's Disease Cohort.

Lee SY, Ryu HJ, Seo JW, Noh MS, Cheon SM, Kim JW.

J Clin Neurol. 2017 Jan;13(1):21-26. doi: 10.3988/jcn.2017.13.1.21. Epub 2016 Oct 7.

3.

Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's Disease.

Almeida OP, McCaul K, Hankey GJ, Yeap BB, Golledge J, Flicker L.

PLoS One. 2016 Sep 30;11(9):e0163781. doi: 10.1371/journal.pone.0163781. eCollection 2016.

4.

Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression.

Mariani E, Frabetti F, Tarozzi A, Pelleri MC, Pizzetti F, Casadei R.

PLoS One. 2016 Sep 9;11(9):e0161567. doi: 10.1371/journal.pone.0161567. eCollection 2016.

5.

Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.

Wang JW, Zhang YQ, Zhang XH, Wang YP, Li JP, Li YJ.

PLoS One. 2016 Jun 1;11(6):e0156721. doi: 10.1371/journal.pone.0156721. eCollection 2016.

6.

Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report.

Um YH, Kim TW, Jeong JH, Seo HJ, Han JH, Hong SC, Jung WS, Choi WH, Lee CU, Lim HK.

Psychiatry Investig. 2016 May;13(3):364-9. doi: 10.4306/pi.2016.13.3.364. Epub 2016 May 18.

7.

An update on the diagnosis and treatment of Parkinson disease.

Rizek P, Kumar N, Jog MS.

CMAJ. 2016 Nov 1;188(16):1157-1165. Epub 2016 May 24. Review. No abstract available.

PMID:
27221269
8.

Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.

Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, Weintraub D.

Parkinsonism Relat Disord. 2016 Jun;27:102-6. doi: 10.1016/j.parkreldis.2016.03.006. Epub 2016 Mar 12.

9.

Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort.

Fernandes GC, Socal MP, Schuh AF, Rieder CR.

Parkinsons Dis. 2015;2015:959304. doi: 10.1155/2015/959304. Epub 2015 Dec 27.

10.

Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study.

Dufek M, Rektorova I, Thon V, Lokaj J, Rektor I.

Parkinsons Dis. 2015;2015:898192. doi: 10.1155/2015/898192. Epub 2015 Aug 16.

11.

Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.

Alshammari TM, AlMutairi EN.

Saudi Pharm J. 2015 Jan;23(1):28-32. doi: 10.1016/j.jsps.2014.04.005. Epub 2014 Apr 30.

12.

Changes of brain gray matter structure in Parkinson's disease patients with dementia.

Xia J, Miu J, Ding H, Wang X, Chen H, Wang J, Wu J, Zhao J, Huang H, Tian W.

Neural Regen Res. 2013 May 15;8(14):1276-85. doi: 10.3969/j.issn.1673-5374.2013.14.004.

13.

Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Kostic VS, Ling H, Meissner WG, Poewe W, Semnic M, Seppi K, Takeda A, Weintraub D, Wenning GK; Movement Disorders Society MSA (MODIMSA) Study Group.

Mov Disord. 2014 Jun;29(7):857-67. doi: 10.1002/mds.25880. Epub 2014 Apr 18. Review.

14.
15.

Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors.

Wang Q, Zhang Z, Li L, Wen H, Xu Q.

Clin Interv Aging. 2014 Feb 12;9:275-81. doi: 10.2147/CIA.S47367. eCollection 2014.

16.

Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson's disease.

Muthukumaran K, Leahy S, Harrison K, Sikorska M, Sandhu JK, Cohen J, Keshan C, Lopatin D, Miller H, Borowy-Borowski H, Lanthier P, Weinstock S, Pandey S.

BMC Neurosci. 2014 Jan 31;15:21. doi: 10.1186/1471-2202-15-21.

17.

Economic conditions at the time of birth and cognitive abilities late in life: evidence from ten European countries.

Doblhammer G, van den Berg GJ, Fritze T.

PLoS One. 2013 Sep 11;8(9):e74915. doi: 10.1371/journal.pone.0074915. eCollection 2013.

18.

Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.

Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M.

Parkinsons Dis. 2012;2012:198316. doi: 10.1155/2012/198316. Epub 2012 Jul 25.

19.

Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Meireles J, Massano J.

Front Neurol. 2012 May 25;3:88. doi: 10.3389/fneur.2012.00088. eCollection 2012.

20.

Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest.

Falcone DC, Wood EM, Xie SX, Siderowf A, Van Deerlin VM.

J Genet Couns. 2011 Aug;20(4):384-95. doi: 10.1007/s10897-011-9362-0. Epub 2011 Apr 8.

Supplemental Content

Support Center